Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

THE EFFECT OF CRP/LYMPHOCYTE AND NEUTROPHIL/LYMPHOCYTE RATIOS ON LENGTH OF HOSPITAL STAY AND MORTALITY IN PATIENTS ADMITTED TO THE BURN UNIT

NCT07855432 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2020-01-01
Last updated
2026-10-02

Condition(s) studied

Burn

Investigational drug(s) / intervention(s)

Routine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission.

Routine blood samples collected for CRP, neutrophil, and lymphocyte counts during ICU admission.: Routinely checked complete blood count and biochemistry tests

Study summary

This retrospective study aims to evaluate the prognostic value of systemic inflammatory markers, specifically the C-reactive protein-to-lymphocyte ratio (CLR) and neutrophil-to-lymphocyte ratio (NLR), in patients admitted to the burn intensive care unit. Burn injury triggers a profound systemic inflammatory response, which significantly influences clinical outcomes. By analyzing medical records, the study investigates whether admission or dynamic changes in CLR and NLR correlate with the length of hospital stay (LOS) and in-hospital mortality. The ultimate goal is to identify cost-effective, readily available biomarkers for early risk stratification in severe burn management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with missing data * Patients with chronic inflammatory disease (optional) * Pediatric patients under 18 years of age * Patients with a hospital stay of less than one day Exclusion Criteria: * Patients with missing data * Patients with chronic inflammatory disease (optional) * Pediatric patients under 18 years of age * Patients with a hospital stay of less than one day

Primary outcome measure(s)

  • In-Hospital Mortality — 01.01.2020 - 31.12.2025
    Evaluation of the association between baseline CRP/lymphocyte ratio (CLR) and neutrophil/lymphocyte ratio (NLR) values upon admission and the occurrence of all-cause in-hospital mortality.

Trial sites (1)

FacilityCityRegionStatus
Samsun Universitesi Samsun Atakum
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07855432 on ClinicalTrials.gov ↗ ← All trials in Turkey